ondansetron has been researched along with Cancer of Jaw in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of a preoperative 4-mg dose of ondansetron given intravenously in preventing postoperative nausea and vomiting after maxillofacial surgery was evaluated in a double-blind randomized study." | 9.08 | The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. ( Campbell, R; Chow, J; Rodrigo, C; Tong, A, 1996) |
| "The efficacy of a preoperative 4-mg dose of ondansetron given intravenously in preventing postoperative nausea and vomiting after maxillofacial surgery was evaluated in a double-blind randomized study." | 5.08 | The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. ( Campbell, R; Chow, J; Rodrigo, C; Tong, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rodrigo, C | 1 |
| Campbell, R | 1 |
| Chow, J | 1 |
| Tong, A | 1 |
1 trial available for ondansetron and Cancer of Jaw
| Article | Year |
|---|---|
The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery.
Topics: Adult; Aged; Anesthesia, Dental; Anesthesia, General; Antiemetics; Chi-Square Distribution; Cleft Pa | 1996 |